Salbutamol was administered to primate model to study the bronchoconstriction in chronic allergic asthma.20 Salbutamol was used as a standard for rapid pharmacokinetic screening of human plasma samples using HPLC.21
Biochem/physiol Actions
β2-adrenoceptor agonist
Salbutamol is a β2 adrenoceptor agonist with short acting bronchodilation and anti-inflammatory effects. It relaxes the airway smooth muscles and inhibits bronchoconstriction induced by adenosine-5′ -monophosphate (AMP).1 Salbutamol is particularly effective in treatment of asthma as it provides immediate relief.2
Features and Benefits
This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
The Lancet. Respiratory medicine, 3(5), 367-376 (2015-02-16)
In patients with severe asthma, tiotropium improves lung function and exacerbation risk when added to high-dose inhaled corticosteroids plus long-acting β2 agonists. We aimed to assess the safety and efficacy of tiotropium in patients with moderate asthma who were symptomatic
Molecular and cellular neurosciences, 95, 59-70 (2019-02-15)
Increasing evidence indicates that, first, the sympathetic nervous system interacts extensively with both vasculature and skeletal muscle fibers near neuromuscular junctions (NMJs) and, second, its neurotransmitter, noradrenaline, influences myofiber molecular composition and function and motor innervation. Since sympathomimetic agents have
Asthma and other airway obstructive disorders are characterized by heightened inflammation and excessive airway epithelial cell reactive oxygen species (ROS), which give rise to a highly oxidative environment. After decades of use, β2-adrenergic receptor (β2AR) agonists remain at the forefront
Combinations of inhaled long-acting bronchodilator therapies such as muscarinic antagonists and β2-agonists may be more effective than monotherapy in the treatment of chronic obstructive pulmonary disease (COPD). This study was a 24-week, Phase III, multicenter, randomized, blinded, double-dummy, parallel-group study
The Journal of allergy and clinical immunology, 136(3), 601-609 (2015-03-10)
Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.